Neuroprotective effect and intraocular penetration of nipradilol, a β-blocker with nitric oxide donative action

Investigative Ophthalmology and Visual Science

Volumn 42, Issue 3, 2001, Pages 688-694

  Mizuno, K ^a   Koide, T ^a   Yoshimura, M ^a   Araie, M ^a  

^a KOWA COMPANY LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIGLAUCOMA AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BUNAZOSIN; CARBON 14; DIZOCILPINE; ENDOTHELIN 1; N METHYL DEXTRO ASPARTIC ACID; NIPRADILOL; NITRIC OXIDE; NITROPRUSSIDE SODIUM; TIMOLOL;

ANIMAL CELL; ANIMAL MODEL; ARTERY CONSTRICTION; ARTICLE; CELL COUNT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA ARTERY; RETINA DISEASE; RETINA INJURY;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BLOOD-RETINAL BARRIER; CELL COUNT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; MALE; N-METHYLASPARTATE; NEUROPROTECTIVE AGENTS; NITRIC OXIDE; NITRIC OXIDE DONORS; NITROPRUSSIDE; PROPANOLAMINES; QUINAZOLINES; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; RETINA; RETINAL ARTERY; TIMOLOL; VASOCONSTRICTION;

EID: 0035094829     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Vasoactive and β-adrenoceptor blocking properties of 3,4·dihydro-8-(2-hydroxy-3-isopropylamino) propoxy-3-nitroxy-2H-1-benzopyran (K-351). A new antihypertensive agent
2. Effects of nipradilol (K-351) on alpha-adrenoceptor mediated responses in various isolated tissues
3. Vasodilating action of nipradilol (K-351) in the pithed rat pretreated with dihydroergotamine
4. Canine retinal arterial and arteriolar dilatation induced by nipradilol, a possible glaucoma therapeutic
5. Effects of topical nipradilol, a β-blocking agent with α-blocking and nitroglycerin-like activities, on aqueous humor dynamics and fundus circulation
6. Effects of topical nipradilol, a β blocking agent with α blocking and nitroglycerin-like activities, on intraocular pressure and aqueous dynamics in humans
7. Phase III comparative clinical study on KT-210 in patients with primary open-angle glaucoma and ocular hypertension: Multicenter cooperative between-group comparative double-blind clinical trial with 0.5% timolol maleate ophthalmic solution
8. Nitric oxide: A review of its role in retinal function and disease
9. Nitric oxide mediates excitotoxic and anoxic damage in rat retinal ganglion cells cocultured with astroglia
10. The role of neuronal and endothelial nitric oxide synthase in retinal excitotoxicity
11. An experimental basis for implicating excitotoxicity in glaucomatous optic neuropathy
12. Potential role of nitric oxide and endothelin in the pathogenesis of glaucoma
13. Inhibition of nitric-oxide 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma
14. A redox based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds
15. Nitrate therapy may retard glaucomatous optic neuropathy perhaps through modulation of glutamate receptors
16. Reduction of infarct size by the NO donors sodium nitroprusside and spermine/NO after transient focal cerebral ischemia in rats
17. Neuroprotective properties of nitric oxide
18. -
19. Pharmacokinetic and pharmacodynamic properties and therapeutic use of bunazosin in hypertension: A review
20. ω-nitro-L-arginine methyl ester protects retinal neurons against N-methyl-D-aspartate-induced neurotoxicity in vivo
21. Pressure-induced retinal ischemia in rats: An experimental model for quantitative study
22. Ischemia and reperfusion-induced histologic changes in the rat retina
23. Neuroprotective effects of eliprodil in retinal excitotoxicity and ischemia
24. N-Methyl-D-Aspartate (NMDA)-induced apoptosis in rat retina
25. Open-angle glaucoma
26. The glutamate receptor ion channels
27. Excitotoxins: A possible new mechanism for the pathogenesis of ischemic retinal damage
28. Glutamate release in experimental ischemia of the retina: An approach using microdialysis
29. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma
30. The toxic effect of sodium 1-glutamate on the inner layers of retina
31. Pharmacological approaches to the treatment of ischemic neuronal damage
32. Histologic changes in the inner retina of albino rats following intravitreal injection of monosodium L-glutamate
33. N-methyl-D-aspartate antagonists prevent kainate neurotoxicity in rat retinal ganglion cells in vitro
34. N-methyl-D-aspartate-induced neurotoxicity in the adult rat retina
35. Greater sensitivity of larger retinal ganglion cells to NMDA-mediated cell death
36. Expression of NMDA and high-affinity kainate receptor subunit mRNAs in the adult rat retina
37. Impaired hyaloidal circulation function and uncoordinated ocular growth patterns in experimental retinopathy of prematurity
38. Some cardiovascular effects of timolol a new β-adrenergic blocking agent
39. In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent
40. Topically applied betaxolol attenuates NMDA-induced toxicity to ganglion cells and the effects of ischaemia to the retina
41. Functional role of nitric oxide in regulation of ocular blood flow
42. Redox mechanisms at the glutamate synapse and their significance: A review
43. 14C] KT-210 (nipradilol ophthalmic solution) in rabbits, 3: Metabolism in plasma, eye and aqueous humor after single instillation to rabbits
44. Periocular accumulation of timolol and betaxolol in glaucoma patients under long-term therapy
45. Drug delivery for posterior segment eye disease
46. 3H]noradrenaline uptake by β-adrenoceptor blocking drugs: Influence of lipophilicity